Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

NCT06058234 · clinicaltrials.gov ↗

RECRUITING

Status

8680

Enrollment

FED

Sponsor class

Conditions

Mild Alzheimer's Disease
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Interventions

DRUG: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

Sponsor

Centers for Medicare and Medicaid Services/ Coverage and Analysis Group